TKPHF Stock Chart & Stats
$36.82
-$3.31(-9.60%)
At close: 4:00 PM EDT
$36.82
-$3.31(-9.60%)
Day’s Range― - ―
52-Week Range$26.02 - $42.00
Previous CloseN/A
Volume284.00
Average Volume (3M)4.06K
Market Cap
$65.01B
Enterprise Value$12.75T
Total Cash (Recent Filing)$527.58B
Total Debt (Recent Filing)$4.94T
Price to Earnings (P/E)55.9
Beta-0.30
Next Earnings
Oct 29, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield3.08%
Share Statistics
EPS (TTM)114.22
Shares Outstanding1,602,218,500
10 Day Avg. Volume4,886
30 Day Avg. Volume4,064
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)1.15
Price to Sales (P/S)1.98
P/FCF Ratio11.70
Enterprise Value/Market Cap196.15
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.44
Enterprise Value/Ebitda9.89
Forecast
1Y Price Target
$44.40Price Target Upside20.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.79
Revenue Forecast (FY)$29.92B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSubstantial operating and free cash flow gives Takeda capacity to fund research, launches, debt obligations, and shareholder returns internally. This supports resilience across its global product portfolio and provides financial flexibility to convert pipeline opportunities into commercial growth.
Pipeline And Launch MomentumMultiple late-stage assets and upcoming launches diversify Takeda’s future growth beyond mature products. Positive clinical data, regulatory milestones, and launch preparation can strengthen the portfolio and create additional revenue streams over the next several quarters.
Improving LeverageImproving leverage and a growing equity base strengthen Takeda’s financial foundation after its acquisition-driven expansion. Lower relative debt can reduce balance-sheet pressure and preserve capacity for R&D, business development, and commercialization investment.
Bears Say
Mature Product And Exclusivity PressureLoss of exclusivity and generic erosion can create sustained revenue pressure as mature products lose pricing power and market share. Takeda must replace these declines with launches and pipeline successes, making portfolio transition execution important for medium-term growth.
Thin And Volatile Net ProfitabilityLow and variable net profitability means revenue growth does not consistently translate into strong bottom-line earnings. Sensitivity to costs, non-operating items, and other below-the-line pressures may constrain retained capital and make earnings power less predictable.
Softening Cash ConversionRecent cash-flow softness reduces the amount of internally generated funding available for investment and capital returns, even though absolute cash generation remains substantial. Working-capital effects and the Protagonist payment also show that cash conversion can be uneven.
TKPHF FAQ
What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest stock price was $26.02 and its highest was $42.00 in the past 12 months.
What is Takeda Pharmaceutical Co Ltd’s market cap?
Takeda Pharmaceutical Co Ltd’s market cap is $65.01B.
When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 5 days.
How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
Takeda Pharmaceutical Co Ltd released its earnings results on Jul 30, 2026. The company reported $0.457 earnings per share for the quarter, beating the consensus estimate of $0.347 by $0.11.
Is Takeda Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Takeda Pharmaceutical Co Ltd pay dividends?
Takeda Pharmaceutical Co Ltd pays a Semiannually dividend of $0.65 which represents an annual dividend yield of 3.08%. See more information on Takeda Pharmaceutical Co Ltd dividends here
What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
Takeda Pharmaceutical Co Ltd’s EPS estimate is 0.29.
How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
Takeda Pharmaceutical Co Ltd has 1,602,218,500 shares outstanding.
What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
Takeda Pharmaceutical Co Ltd reported an EPS of $0.457 in its last earnings report, beating expectations of $0.347. Following the earnings report the stock price went down -5.251%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in TKPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
TKPHF Company Deck
TKPHF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of modest near-term CER declines and cash-flow timing effects against substantial positive developments: strong FX-driven reported results, confirmation of transformation-led funding for launches, multiple imminent regulatory and commercial milestones (ORZEYFUL approval in China; rusfertide priority review; superior zasocitinib data), and a robust late-stage pipeline with several programs moving to pivotal stages. While Q1 contained some one-time impacts, transitional investment effects and product-specific headwinds, the combination of pipeline momentum, launch readiness and a maintained full-year financial outlook suggests the company is positioned to convert R&D progress into revenue growth later in the year.View all TKPHF earnings summariesTKPHF Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$44.40
▲(20.60% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
―
Shionogi & Co
―
Nippon Shinyaku Co., Ltd.
―
Ownership Overview
0.19% Insiders
8.95% Mutual Funds
<0.01% Other Institutional Investors
75.10% Public Companies and
Individual Investors









